[Radionuclide studies of atherosclerosis]

Area of Science:

• Nuclear Medicine
• Radiopharmaceutical Development
• Cardiovascular Imaging
• Cerebrovascular Imaging

Background:

• Cerebral perfusion disturbances due to arteriosclerosis require advanced diagnostic tools.
• Cardiovascular nuclear medicine benefits from novel radiotracers for evaluating myocardial perfusion and metabolism.
• Direct imaging of atherosclerosis is an ongoing area of research.

Purpose of the Study:

• To introduce new Tc-99m-labeled agents for improved brain perfusion imaging.
• To highlight advancements in Tc-99m-labeled cardiovascular agents.
• To discuss emerging tracers for evaluating coronary sclerosis and direct atherosclerosis imaging.

Main Methods:

• Development and application of Tc-99m-HMPAO and Tc-99m-ECD for brain perfusion.
• Utilization of Tc-99m-MIBI, Teboroxime, and Tetrofosmin in cardiovascular nuclear medicine.
• Investigation of I-123-MIBG and I-123-BMIPP for coronary sclerosis and myocardial metabolism.
• Exploration of In-111-polyclonal immunoglobulin G and Tc-99m-low density lipoprotein for direct atherosclerosis imaging.

Main Results:

• New Tc-99m agents provide superior imaging for cerebral perfusion compared to I-123-IMP.
• Availability of advanced Tc-99m compounds for cardiovascular assessment.
• I-123-MIBG and I-123-BMIPP show promise for studying coronary artery disease and myocardial fatty acid metabolism.
• Investigational agents are being explored for direct visualization of atherosclerosis.

Conclusions:

• New Tc-99m radiotracers significantly enhance the study of cerebral perfusion disturbances.
• Advancements in Tc-99m and I-123 labeled agents are revolutionizing cardiovascular nuclear medicine.
• Ongoing research into novel tracers aims for direct imaging of atherosclerosis.